glp-1 obesity drug market news today Receptor Agonist Growth Analysis How Supply and Demand for

Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor

The drug exhibited a half-life of approximately 10 days

Hamann CR, Chung C, Kaffenberger BH

Patients who take medications Early research shows these medications may affect the brain's reward and motivation systems, showing promise for nearly 13.6 million employees who suffer from substance use and alcohol use disorders, according to Nzinga Harrison, co-founder and chief medical officer of Eleanor Health

Angermueller, C

However, through the $10 billion acquisition of clinical-stage biotech company Metsera in November 2025, Pfizer secured a next-generation obesity pipeline after an aggressive bidding war with Novo